Wegovy coverage by health insurance
Many patients want to know whether their health insurance will pay for Wegovy. The short answer for Germany is: when Wegovy is used for weight reduction, statutory health insurance providers generally do not cover the cost.
Wegovy is a prescription-only medication containing the active ingredient semaglutide. It is used for weight management in addition to a reduced-calorie diet and increased physical activity. A general medical overview of its effects, use, and eligibility criteria is available on the page about the Wegovy injection for weight loss. This page focuses specifically on cost coverage, statutory health insurance, private reimbursement, and self-pay costs.
Important: This information does not replace medical advice or a binding coverage decision from your health insurer. Whether Wegovy is medically appropriate, whether a prescription can be issued, and whether reimbursement may be possible must always be assessed individually.
Does health insurance cover Wegovy?
Statutory health insurance providers in Germany generally do not pay for Wegovy when it is used for weight reduction. The Federal Joint Committee, known as the G-BA, has classified Wegovy with the active ingredient semaglutide as a so-called lifestyle medication when used for weight reduction. Medications used for weight loss, appetite suppression, or body weight regulation are generally excluded from reimbursement under statutory health insurance.
This does not mean that obesity is medically insignificant. It also does not mean that Wegovy is generally unsuitable for eligible patients. What matters is the distinction between medical eligibility, physician prescription, and health insurance reimbursement. These three levels are often confused, but they should be assessed separately.
A broader explanation of reimbursement for different weight loss medications is available on the page about health insurance and weight loss medications. This page focuses specifically on when and why Wegovy is or is not covered.
Why do statutory health insurers usually not cover Wegovy?
Statutory health insurance in Germany is bound by the statutory benefits catalog. Medications used for weight reduction, appetite suppression, or body weight regulation are generally not covered by statutory health insurance. Wegovy falls under this rule when it is used for weight management.
For patients with statutory insurance, the main question is usually not whether a specific health insurer is especially flexible. The decisive issue is whether the medication may legally be prescribed at the expense of statutory health insurance for the specific purpose. For Wegovy used for weight management, this is generally not the case.
| Question | Assessment for Wegovy | What this means for patients |
|---|---|---|
| Is Wegovy prescription-only? | Yes, Wegovy requires a prescription. | It should only be used after a medical assessment. |
| Is Wegovy approved for weight management? | Yes, for certain BMI criteria and weight-related comorbidities. | Medical eligibility must be assessed individually. |
| Does statutory health insurance pay? | For weight reduction, generally no. | Patients with statutory insurance usually pay the costs themselves. |
| Can private insurance pay? | This depends on the policy and individual review. | A written request before starting treatment is advisable. |
Wegovy for obesity: Which criteria are medically relevant?
Wegovy is approved in the EU for weight management. In adults, it may be considered in addition to diet and physical activity if obesity is present or if overweight is accompanied by at least one weight-related comorbidity. Commonly relevant criteria include a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity.
Possible comorbidities include type 2 diabetes, prediabetes, high blood pressure, lipid disorders, sleep apnea, or cardiovascular disease. However, these criteria primarily describe who may be medically eligible for Wegovy. They do not automatically mean that health insurance will pay for Wegovy.
- BMI of 30 or higher: Wegovy may be medically assessed in patients with obesity.
- BMI of 27 or higher: Assessment may be relevant if additional weight-related comorbidities are present.
- Medical assessment: Existing conditions, current medications, side effect risks, and previous measures must be considered.
- No automatic reimbursement: Even if medical criteria are met, statutory coverage for weight reduction is usually excluded.
If you would like to have your medical eligibility assessed, you can schedule an appointment for medical weight loss. Diagnosis, BMI, comorbidities, treatment goals, and potential costs can be discussed individually.
Wegovy and diabetes: Why the indication matters
Wegovy contains semaglutide, but it is not the same as Ozempic. Both medications contain the same active ingredient, but they are intended for different medical uses. Ozempic is used to treat adults with type 2 diabetes. Wegovy is approved for weight management.
This distinction is important for reimbursement. Semaglutide medications that are not approved for weight management and are used for other indications, such as type 2 diabetes, do not automatically fall under the same reimbursement exclusion as Wegovy for weight reduction. For this reason, reimbursement should never be inferred broadly from “semaglutide” alone.
For a more precise diabetes-related assessment, the page on Ozempic coverage by health insurance is more relevant. This Wegovy page should not try to fully cover the Ozempic search intent, so the topics remain clearly separated.
Wegovy and Techniker Krankenkasse: Are there special rules?
Many search queries refer to specific health insurers, such as Techniker Krankenkasse. However, the same statutory framework generally applies to all statutory health insurance providers. For Wegovy, it is therefore usually not decisive whether someone is insured with Techniker Krankenkasse, AOK, Barmer, DAK, or another statutory health insurer.
What matters is whether Wegovy may be prescribed at the expense of statutory health insurance for the specific use. When used for weight reduction, Wegovy is generally not a statutory health insurance benefit. An individual inquiry with the health insurer may be reasonable in special situations, but it does not replace medical assessment and does not guarantee reimbursement.
Key point: For Wegovy, reimbursement does not primarily depend on the name of the statutory health insurer. It depends on the indication, the reimbursement exclusion, and the individual medical assessment.
How can Wegovy cost coverage be reviewed?
For patients with statutory health insurance, cost coverage for Wegovy used for weight reduction is usually not realistic. For private health insurance or individual inquiries, it may still be useful to prepare the medical background carefully. Before any coverage request, a physician should assess whether Wegovy is medically appropriate at all.
The following points may be relevant for a structured review:
- Diagnosis: Is there obesity, overweight with comorbidities, or another relevant medical condition?
- BMI and weight history: What is the current BMI and how has weight developed over time?
- Comorbidities: Are high blood pressure, prediabetes, type 2 diabetes, sleep apnea, or lipid disorders present?
- Previous measures: Have nutrition, physical activity, behavioral therapy, or other medical approaches already been tried?
- Treatment plan: Is there a physician-supervised concept including dosage, follow-up care, and side effect management?
- Cost framework: Are medication costs, consultations, follow-up appointments, and the accompanying program clearly documented?
If you have questions about approval status, indications, and off-label use, the article on GLP-1 agonists and approved indications can provide additional context.
How much does Wegovy cost without health insurance coverage?
If health insurance does not pay for Wegovy, patients generally have to finance the treatment themselves. Private costs depend on dosage, pack size, treatment duration, availability, and medical supervision. Monthly costs often amount to several hundred euros.
Important: The medication price alone is not the same as the total cost of medically supervised treatment. In responsible Wegovy treatment, medical assessment, prescription, patient education, dosage, follow-up care, and side effect management should be included.
The page on prices for medical weight loss provides orientation for financial planning. The specific cost should always be clarified as part of an individual treatment plan.
Wegovy price, dosage, and treatment duration
The duration of Wegovy treatment is not determined by a fixed rule. It depends on medical eligibility, tolerability, treatment goals, weight development, and physician assessment. Wegovy is typically used once weekly as a subcutaneous injection. The dose is usually increased gradually to improve tolerability.
Search queries such as “Wegovy price,” “Wegovy dosage,” and “Wegovy side effects” often appear together with insurance-related questions. However, this page primarily addresses cost coverage. Details on use and dose escalation are available on the page about Wegovy dosage and use.
| Topic | Relevant to the cost question? | Assessment |
|---|---|---|
| Dosage | Yes | The dose can influence monthly costs. |
| Treatment duration | Yes | Longer treatment means higher total costs. |
| Side effects | Indirectly | Tolerability can influence whether treatment is continued. |
| Accompanying program | Yes | Medical care, coaching, and follow-up appointments may be part of the total cost. |
What alternatives are available if health insurance does not cover Wegovy?
If Wegovy is not covered by health insurance, this does not automatically mean that treatment is impossible. Depending on the individual starting point, different options may be appropriate. Which alternative fits best should always be assessed medically.
- Medically supervised self-pay program: Wegovy can be privately financed if medical eligibility has been confirmed.
- Other weight loss medications: Depending on diagnosis, comorbidities, and tolerability, another medication may be considered.
- Tirzepatide as a possible alternative: For suitable patients, treatment with Mounjaro may be reviewed by a physician.
- Structured injection therapy: For certain patients, weight loss injections may be part of a medically supervised program.
- Non-medication treatment: For some people, a program for medical weight loss with nutrition, physical activity, and follow-up care may be more appropriate.
For a comparison of two frequently searched options, the article Wegovy vs. Mounjaro comparison provides additional orientation. However, the decision for or against a specific medication should not be based on a comparison article alone.
When should Wegovy not be used without medical supervision?
Wegovy is prescription-only and should not be used without medical supervision. Before treatment begins, possible contraindications, existing medical conditions, current medications, and individual risks must be reviewed. Side effects such as nausea, vomiting, diarrhea, constipation, or abdominal pain should also be taken seriously and discussed with a physician.
Special caution is needed if Wegovy is offered without a prescription, through unsafe sources, or without medical monitoring. Counterfeit, improperly stored, or incorrectly used products can pose significant risks. Treatment should therefore only take place through reputable medical structures.
If the question is whether another medication may be more suitable than Wegovy, Mounjaro coverage by health insurance should be considered separately. This keeps active ingredient comparison, medical eligibility, and reimbursement clearly separated.
Frequently asked questions about Wegovy and health insurance
When does health insurance pay for Wegovy?
When used for weight reduction, statutory health insurance generally does not pay for Wegovy. The reason is the reimbursement exclusion for medications used to regulate body weight. For private health insurance, reimbursement depends on the policy, medical justification, and individual review.
Is Wegovy covered by health insurance for obesity?
Wegovy is approved for weight management in obesity or overweight with a weight-related comorbidity. Even so, statutory health insurance providers generally do not cover the cost when Wegovy is used for weight reduction. Approval and reimbursement are two different questions.
Does Techniker Krankenkasse cover Wegovy?
The same statutory framework generally applies to all statutory health insurance providers. When used for weight reduction, Wegovy is generally not a statutory health insurance benefit. This applies regardless of whether someone is insured with Techniker Krankenkasse or another statutory health insurer.
Can a general practitioner prescribe Wegovy?
In principle, Wegovy can be prescribed by a physician if the medical requirements are met and there are no relevant contraindications. Whether a general practitioner, specialist, or specialized practice is the right point of contact depends on the individual situation.
How much does Wegovy cost without health insurance?
Private costs depend on dosage, pack size, treatment duration, and medical supervision. Monthly costs often amount to several hundred euros. Additional costs for consultations, follow-up care, and accompanying programs may apply.
Is Wegovy the same as Ozempic?
No. Both medications contain semaglutide, but they are intended for different uses. Ozempic is used for type 2 diabetes, while Wegovy is used for weight management. This distinction is especially important for reimbursement.
Can I have my eligibility for Wegovy checked in advance?
Yes. During a medical consultation, a physician can assess whether Wegovy is medically appropriate, which alternatives may be available, which risks need to be considered, and what costs are likely. This does not guarantee health insurance reimbursement.
Sources
- Federal Joint Committee, G-BA: Wegovy and the statutory reimbursement exclusion for weight loss medications.
- Federal Joint Committee, G-BA: Pharmaceutical Directive Annex II: semaglutide and Wegovy.
- Federal Joint Committee, G-BA: reimbursement exclusion for lifestyle medications.
- European Medicines Agency: Wegovy EPAR and approved use in weight management.